References: Hepatocellular carcinoma

Allard N, Cabrie T, Wheeler E, Richmond J, MacLachlan J, Emery J, et al. The challenge of liver cancer surveillance in general practice: do recall and reminder systems hold the answer? Aust Fam Physician 2017;46(11):859–64. https://www.ncbi.nlm.nih.gov/pubmed/29101924
Australasian Hepatology Association (AHA). AHA consensus-based nursing guidelines for the care of people with hepatitis B, hepatitis C, advanced liver disease and hepatocellular carcinoma. Melbourne: AHA; 2019. https://www.hepatologyassociation.com.au/resources/consensus-based-nursing-guidelines/
Bruix J, da Fonseca LG, Reig M. Insights into the success and failure of systemic therapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2019;16(10):617–30. https://www.ncbi.nlm.nih.gov/pubmed/31371809
European Association for the Study of the Liver. EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69(1):182–236. https://www.ncbi.nlm.nih.gov/pubmed/29628281
Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018;391(10127):1301–14. https://www.ncbi.nlm.nih.gov/pubmed/29307467
Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018;67(1):358–80. https://www.ncbi.nlm.nih.gov/pubmed/28130846
Hepatitis B Consensus Statement Working Group. Australian consensus recommendations for the management of hepatitis B infection. Melbourne: Gastroenterological Society of Australia; 2022. https://www.gesa.org.au/index.cfm//resources/clinical-practice-resources/hepatitis-b-virus-hbv-consensus-statement/
Hong TP, Gow PJ, Fink M, Dev A, Roberts SK, Nicoll A, et al. Surveillance improves survival of patients with hepatocellular carcinoma: a prospective population-based study. Med J Aust 2018;209(8):348–54. https://www.ncbi.nlm.nih.gov/pubmed/30309301
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 2018;391(10126):1163–73. https://www.ncbi.nlm.nih.gov/pubmed/29433850
Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology 2018;67(1):381–400. https://www.ncbi.nlm.nih.gov/pubmed/28859222
Majumdar A, Roccarina D, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with early- or very early-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011650. https://www.ncbi.nlm.nih.gov/pubmed/28351116
Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, Abecassis MM, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68(2):723–50. https://www.ncbi.nlm.nih.gov/pubmed/29624699
Roberts LR, Sirlin CB, Zaiem F, Almasri J, Prokop LJ, Heimbach JK, et al. Imaging for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatology 2018;67(1):401–21. https://www.ncbi.nlm.nih.gov/pubmed/28859233
Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev 2017;3:CD011649. https://www.ncbi.nlm.nih.gov/pubmed/28281295
Tzartzeva K, Obi J, Rich NE, Parikh ND, Marrero JA, Yopp A, et al. Surveillance Imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology 2018;154(6):1706-18 e1. https://www.ncbi.nlm.nih.gov/pubmed/29425931